Skip to content
DataLookout
Menu

NCT06690775

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 55 words
    • Enrollment closed, study ongoing
    • Trial sites expanded: 66 → 81 locations
  2. Minor Study sites: 56 to 66v17
  3. Minor Study sites: 53 to 56v16
  4. Minor Study sites: 42 to 53v15
  5. Minor Study sites: 40 to 42v14
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study sites: 37 to 40v13
  2. Minor Study sites: 33 to 37v12
  3. Minor Study sites: 28 to 33v11
  4. Minor Study sites: 24 to 28v10
  5. Minor Study sites: 21 to 24v9
  6. Minor Study sites: 17 to 21v8
  7. Minor Study sites: 15 to 17v7
  8. Minor Site details revised at 4 of 15 sitesv6
  9. Minor Study sites revised (15)v5
  10. Notable Eligibility criteria revised
    • Study sites: 1 to 15
    v4
  11. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2024 to Nov 20, 2024
    v3
  12. Minor Study title shortened, about 1 wordv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6
Timeframe: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

Secondary (6)

Duration of Response (DOR)
Objective Response Rate (ORR)
Progression-free Survival (PFS)
Overall Survival (OS)
Incidence and severity of AEs and clinical laboratory abnormalities per CTCAE v5.0
Show 1 moreShow less
CA-125 response per Gynecological Cancer Intergroup (GCIG) criteria

Arms and interventions

Cohort 1Experimental

Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

Cohort 2Experimental

Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

Cohort 3Experimental

Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

Drugs: TORL-1-23, Pegfilgrastim (drug)

Sites

81 sites in 13 countries

United States 30, Canada 8, South Korea 7, Australia 5, Belgium 4, Czechia 4, Germany 4, Italy 4, Austria 3, France 3, Ireland 3, Singapore 3, Spain 3